MINDMAZE THERAPEUTICS HOLDING SA (SW:MMTX) — Market Cap & Net Worth
Market Cap & Net Worth: MINDMAZE THERAPEUTICS HOLDING SA (MMTX)
MINDMAZE THERAPEUTICS HOLDING SA (SW:MMTX) has a market capitalization of $46.82 Million (CHF37.04 Million) as of August 4, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #22091 globally and #201 in its home market, demonstrating a 48.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MINDMAZE THERAPEUTICS HOLDING SA's stock price CHF0.24 by its total outstanding shares 157602044 (157.60 Million). Review MMTX current and long-term liabilities to assess the company's total debt and financial obligations.
MINDMAZE THERAPEUTICS HOLDING SA Market Cap History: 2025 to 2026
MINDMAZE THERAPEUTICS HOLDING SA's market capitalization history from 2025 to 2026. Data shows growth from $378.58 Million to $46.82 Million (0.00% CAGR).
MINDMAZE THERAPEUTICS HOLDING SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MINDMAZE THERAPEUTICS HOLDING SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
589.69x
MINDMAZE THERAPEUTICS HOLDING SA's market cap is 589.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $378.58 Million | $642.00K | -$9.91 Million | 589.69x | N/A |
Competitor Companies of MMTX by Market Capitalization
Companies near MINDMAZE THERAPEUTICS HOLDING SA in the global market cap rankings as of August 4, 2026.
Key companies related to MINDMAZE THERAPEUTICS HOLDING SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
MINDMAZE THERAPEUTICS HOLDING SA Historical Marketcap From 2025 to 2026
Between 2025 and today, MINDMAZE THERAPEUTICS HOLDING SA's market cap moved from $378.58 Million to $ 46.82 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF46.82 Million | -87.63% |
| 2025 | CHF378.58 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of MINDMAZE THERAPEUTICS HOLDING SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $46.82 Million USD |
| MoneyControl | $46.82 Million USD |
| MarketWatch | $46.82 Million USD |
| marketcap.company | $46.82 Million USD |
| Reuters | $46.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MINDMAZE THERAPEUTICS HOLDING SA
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outp… Read more